Drug Profile
Vosoritide - BioMarin Pharmaceutical
Alternative Names: BMN-111; Modified C-natriuretic peptide - BioMarin Pharmaceutical; Modified recombinant human C-type natriuretic peptide - BioMarin Pharmaceutical; ProCNP38; VOXZOGOLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Class Cyclic peptides; Natriuretic agents; Natriuretic peptides; Recombinant proteins
- Mechanism of Action Atrial natriuretic factor receptor B agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Achondroplasia
- Phase II Short stature